MAPT and Alzheimer disease: We utilized APOE3- and APOE4- carrying iPSC-derived BBB cells and investigated molecular changes following FUS+MB as well as the FUS+MB-mediated delivery of two therapeutic AD antibodies: an Aducanumab analogue (anti-Aβ antibody, commercially known as AduhelmTM) 34, 35, and RNF5, an anti-Tau antibody, which has recently been shown to be efficient in reducing p-Tau levels in an animal model with Tau pathology 36.